Jade Biosciences delays Phase 3 trial start for JADE101

BTIG reiterated a Buy rating on Jade Biosciences with a $77 price target, implying a 431% upside from the Oct 26 close of $14.50. The target is based on strong clinical data for JADE101, showing a 70% reduction in IgA levels, and rapid clinical trial advancements, including a Phase 3 trial expected in 4Q26.

HC Wainwright & Co. reiterated a Buy rating on Jade Biosciences with a $55 price target, implying a 291.5% upside from the Sep 30 close. The rating is based on the company's strong pipeline, particularly JADE101 in Phase 1 trials, and favorable valuation metrics according to the analyst.

Wedbush reiterated an Outperform rating and $47 price target for Jade Biosciences (JBIO) after positive preclinical data for JADE301. The stock is up 54% over the past year. Analysts expect key data readouts in 2027. Jade Biosciences has no debt and a strong cash position. Multiple analysts have raised price targets and maintained positive ratings.

Jade Biosciences (JBIO) is advancing JADE301, an investigational antibody, toward a Phase 1 trial for dermatomyositis after preclinical studies showed it selectively blocks IFN-Beta. The drug demonstrated high potency and extended half-life, with plans for a trial in Q4 2026. JBIO stock closed at $14.18, down 1.18%.

Jade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 30, 2026, Jade Biosciences, Inc. (“Jade”) announced preclinical data characterizing JADE301, its anti-interferon beta (“IFN-ß”) monoclonal antibody in development for dermatomyositis (“DM”), a rare, chronic and debilitating autoimmune disease

Jade Biosciences (JBIO) reported Q2 2026 net loss of $55.8M and cash, cash equivalents and investments of $461.2M as of June 30, 2026, saying it funds operations into Q4 2028. R&D was $50.1M and G&A $8.9M. The company advanced JADE101 to Phase 2/3 and updated progress on JADE201 and JADE301.